Vanguard Group Inc. Has $1.77 Billion Position in Hologic, Inc. $HOLX

Vanguard Group Inc. cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,213,728 shares of the medical equipment provider’s stock after selling 587,955 shares during the period. Vanguard Group Inc. owned about 0.12% of Hologic worth $1,769,165,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in HOLX. Winnow Wealth LLC acquired a new stake in Hologic during the 3rd quarter worth $26,000. Caitong International Asset Management Co. Ltd boosted its stake in Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the period. Root Financial Partners LLC acquired a new stake in shares of Hologic in the 3rd quarter valued at about $27,000. SJS Investment Consulting Inc. grew its holdings in shares of Hologic by 341.5% during the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 362 shares in the last quarter. Finally, Loomis Sayles & Co. L P bought a new position in shares of Hologic during the 2nd quarter worth approximately $33,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. BNP Paribas Exane downgraded Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research report on Friday, November 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Mizuho downgraded shares of Hologic from an “outperform” rating to a “neutral” rating and raised their price target for the company from $70.00 to $78.00 in a research note on Thursday, October 23rd. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Finally, Evercore lowered shares of Hologic from an “outperform” rating to an “in-line” rating and reduced their price objective for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $78.42.

Hologic Stock Down 0.0%

Shares of NASDAQ:HOLX opened at $75.17 on Friday. The business’s 50 day moving average is $74.91 and its 200 day moving average is $71.80. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.36. The stock has a market cap of $16.78 billion, a price-to-earnings ratio of 31.31, a PEG ratio of 2.24 and a beta of 0.72. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period last year, the company posted $0.87 EPS. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.